Related Experiment Videos
Clinical Use of Interleukin-6 Blockade in Neuroimmunological Disorders
Merve Erdal1, Aylin Arı1, Ahmed Serkan Emekli2
1Department of Pharmacology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye.
Noro Psikiyatri Arsivi
|August 12, 2026
Summary
Interleukin-6 (IL-6) inhibitors show promise for treating neurological disorders by reducing inflammation. While effective in conditions like NMOSD, further research is needed to assess safety and CNS-specific efficacy.
Area of Science:
- Neuroimmunology
- Neuroinflammation
- Cytokine Signaling
Background:
- Interleukin-6 (IL-6) is a cytokine crucial for immune responses, with dual roles in the central nervous system (CNS).
- Dysregulated IL-6 signaling contributes to neuroinflammation and the pathology of various neurological disorders.
- Understanding IL-6 pathways is key to developing targeted therapies for CNS diseases.
Purpose of the Study:
- To review the role of IL-6 in neuroinflammatory processes across neurological diseases.
- To evaluate the therapeutic potential and safety of IL-6 inhibitors, such as tocilizumab and satralizumab.
- To discuss clinical implications and future research directions for IL-6 targeted therapies.
Main Methods:
- Literature review of studies on IL-6 in neurological disorders.
- Analysis of clinical trial data for IL-6 inhibitors.
- Evaluation of safety profiles and off-label use of IL-6 blockade.
Main Results:
- IL-6 receptor blockade, e.g., with tocilizumab, is effective in reducing relapse rates in Neuromyelitis Optica Spectrum Disorder (NMOSD).
- Promising results observed in off-label treatment of MOGAD, epilepsy, and autoimmune encephalitis.
- IL-6 inhibition presents risks including serious infections and paradoxical inflammation.
Conclusions:
- Targeting the IL-6 pathway offers significant therapeutic potential for refractory neuroinflammatory conditions.
- Further research, including large-scale trials and CNS-penetrant inhibitors, is warranted.
- Accessibility and cost remain challenges for widespread clinical application of IL-6 inhibitors.
Related Concept Videos
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...